samedan logo
 
 
spacer
home > pmps > autumn 2020 > spotlight - dose counting for metered-dose inhalers – a real patient need
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Spotlight - Dose Counting for Metered-Dose Inhalers – A Real Patient Need

Asthma and chronic obstructive pulmonary diseases (COPD) are responsible for millions of deaths every year. Controlling and monitoring the treatment for these chronic lung disorders is not only required to reduce healthcare costs related to hospitalisations but a real patient need. A reliable system to support the correct and on-time use of inhalers, without changing the way of using them or adding any steps to their routine, is vital for sufferers.

The majority of marketed metered-dose inhalers (MDIs) offer no practical way for patients or doctors to know how many doses are left in their inhaler – which is especially pertinent in case of emergency. Furthermore, there is a collective requirement to track adherence or compliance to medication. To address these requirements, the FDA published guidance to integrate dose-counting mechanisms into MDI drug products. As per the guidelines, devices should offer either clear numeric counting mechanisms or indication functions – with a colour code function, for example – to ensure the correct number of doses is displayed to patients (1-2). The guidance also encourages drug manufacturers to update existing devices.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
H&T Presspart specialises in industrialising drug delivery devices and components. The products that the company offers its pharmaceutical clients include medical devices, metered-dose inhaler components, and a comprehensive range of dose counting technologies. The company has 50 years’ experience and a worldwide reputation for competence, quality, and innovation in the pharmaceutical sector. H&T Presspart’s Inhalation Product Technology Centre supports its customers through new inhalation product developments and strategic initiatives. H&T Presspart, part of the Heitkamp and Thumann Group, has three European manufacturing sites, in Germany, Spain, and the UK, with sales offices in China, India, Singapore, South America, and the US.
spacer
H&T Presspart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

Risk-Based Inspection Readiness: Reducing Headaches with Advanced Preparation

The Avoca Group

So often, inspections are a major source of stress in the clinical trial environment. This is especially true when processes involved in preparing for an inspection are reactive. But, it doesn’t have to be that way. Using industry-leading practices and resources enables a proactive approach to mitigate—or even eliminate—the pain points associated with preparing for inspections.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement